Evidence map›Paper›PMID 34310866›Full record

Trial reportPharmacology research & perspectives2021

The therapeutic effects of naringenin on bronchial pneumonia in children.

Wenjing Yao, Xiaopeng Zhang, Feng Xu, Chunxia Cao, Tongtong Liu, Yuanyuan Xue

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Wenjing YaoDepartment of Pediatrics, Zibo Central Hospital, Zibo, Shandong, China.
Xiaopeng ZhangDepartment of Pediatrics, Zibo Central Hospital, Zibo, Shandong, China.ORCID 0000-0003-2610-4097
Feng XuDepartment of Pediatrics, Zibo Central Hospital, Zibo, Shandong, China.
Chunxia CaoDepartment of Pediatrics, Zibo Central Hospital, Zibo, Shandong, China.
Tongtong LiuDepartment of Pediatrics, Zibo Central Hospital, Zibo, Shandong, China.
Yuanyuan XueDepartment of Pediatrics, Zibo Central Hospital, Zibo, Shandong, China.
Central Hospital of Zibo · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchial pneumonia in children is a common infectious disease in toddlers and infants, which may cause hyperpyrexia, pulmonary moist rales, and even respiratory failure. Traditional drugs for bronchial pneumonia in children often lead to drug resistance and side effects. Recently, naringenin has been reported to be a potential treatment for several airway inflammatory diseases due to its anti-inflammatory and anti-microbial activities. The current clinical study aimed to evaluate the safety and therapeutic effect of naringenin in treating bronchial pneumonia in children. A total of 180 eligible patients were randomly assigned into naringenin (NAR) group and azithromycin (AZI) group. All participants were required to follow a 5-day oral administration, and their serum cytokine levels were measured during the clinical intervention. After the treatment, the disappearance time of clinical symptoms, and the incidences of complications and adverse reactions were compared between the two groups. Naringenin was able to inhibit inflammation, shorten the disappearance time of clinical symptoms, reduce the incidences of bronchial pneumonia complications and related adverse reactions, and improve the health conditions of the patients. Our results suggested that naringenin was safe and beneficial to children with bronchial pneumonia, providing new insights into the clinical application of naringenin.

Indexed as

Anti-Bacterial AgentsAnti-Inflammatory AgentsAzithromycinBronchopneumoniaChild, PreschoolCytokinesFemaleFlavanonesHumansInfantMaleTreatment OutcomeAnti-Bacterial AgentsAnti-Inflammatory AgentsAzithromycinCytokinesFlavanonesnaringeninbronchial pneumonia in childrenchildrennaringenintherapeutic outcomes

Identifiers

PMID34310866
PMCPMC8312741
OpenAlexW3186620792

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.